TerminatedNot applicableNCT04072393

Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers

Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT. Aerobic exercise has been demonstrated to improve patient quality of life, cardiac outcomes, and cardiorespiratory fitness in patients with cancer receiving cardiotoxic systemic therapies, but the effects of aerobic exercise on patients at high risk for radiation induced heart disease (RIHD) is unknown. In addition, home-based cardiac rehabilitation has not been tested in patients with thoracic cancers.

Checked against the public recordLast updated Jul 12, 2024 · Source: ClinicalTrials.gov

StatusTerminated
PhaseNot applicable
U.S. locations1
SponsorWashington University School of Medicine
01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Washington University School of Medicine
Interventions being studied
Procedure: Home-based cardiac rehabilitation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer. * Planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent. * Willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application * Possess a smart phone or tablet capable of supporting teleHeart application * Willing and eligible to co-enroll in the Cardiovascular Toxicity in Cancer and Improvement in Recovery (SURVIVE) Registry Study (HRPO# 201801031). * At least 18 years of age. * ECOG performance status ≤ 2 * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Exclusion Criteria: * Presence of distant metastatic disease (except patients with lymphoma). * Life expectancy less than 6 months * Patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility * Unable to walk * Presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (CR) * Diagnosis of primary cervical esophageal cancer. * Presence of unstable angina. * Recipient of heart transplant. * Patient on cardiac transplant list or has a ventricular assist device * Patient's baseline weight \> 300 lbs (due to weight limitations of the scale and bioelectrical impedance device) * Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. * Other medical comorbidities that make the patient unable to participate in the CR program or other assessments involved with this study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Washington University School of MedicineSt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 12, 2024. Always confirm current availability with the study team.

View original record ↗